Cancer is a heterogeneous disease caused by diverse genomic alterations in oncogenes
and tumor suppressor genes. Despite recent advances in high-throughput sequencing …

The gut microbiome can influence the development of tumours and the efficacy of cancer
therapeutics 1 , 2 , 3 , 4 – 5 ; however, the multi-omics characteristics of antitumour bacterial …

The core functions of stem cells (SCs) are critically regulated by their cellular redox status.
Glutathione is the most abundant non-protein thiol functioning as an antioxidant and a redox …

Cancer is a very heterogeneous disease, displaying heterogeneity between patients (inter-tumoral
heterogeneity) and heterogeneity within a patient (intra-tumoral heterogeneity). …

Pancreatic cancer exhibits a characteristic tumor microenvironment (TME) due to enhanced
fibrosis and hypoxia and is particularly resistant to conventional chemotherapy. However, …

Gastric cancer (GC) is commonly treated by chemotherapy using 5-fluorouracil (5-FU)
derivatives and platinum combination, but predictive biomarker remains lacking. We develop …

Transglutaminase (TGase) 2 is a ubiquitously expressed enzyme that modifies proteins by
cross-linking or polyamination. An aberrant activity of TGase 2 has implicated its possible …

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. Recent
high-throughput analyses of genomic alterations revealed several driver genes and altered …

Transglutaminase 2 (TGase2) is a ubiquitously expressed enzyme that catalyzes irreversible
post‐translational modification of protein, forming cross‐linked protein aggregates. We …

Metastatic or recurrent colorectal cancer (CRC) patients require systemic chemotherapy, but
the therapeutic options of targeted agents remain limited. CRC patients with KRAS or BRAF …